Ming-He Huang, MD, PhD
Founder and CEO
Dr. Huang is the founder of ICA Therapeutics, LLC and the drug therapy, Reperlin. He is a board-certified cardiologist and medical director of The Coast Heart Clinic in Houston, Texas.
Dr. Ming-He Huang obtained his MD from Shanghai Second Medical School and PhD in Physiology & Biophysics from Dalhousie University in Canada. Subsequently, he completed his postdoctoral cardiovascular research training at Harvard Medical School in Boston. He then completed his Internal Medicine residency at the State University of New York and Cardiology Fellowship with honor at the University of Arizona. He has additional board certificates in Echocardiography and Nuclear cardiology. Dr. Huang is affiliated to the St Luke’s Episcopal Hospital in Houston and Clear Lakes Regional Medical Center.
Dr. Huang currently holds academic positions as Adjunct Associate Professor at the University of Texas Medical Branch (UTMB) and the College of Pharmacy at University of Houston. He has contributed significantly to cardiovascular medicine with numerous publications in highly regarded medical journals. He discovered Intrinsic Cardiac Adrenergic Cells in the heart in 1996. His research was supported by the American Heart Association and National Institutes of Health (NIH). Among many achievements, he was a finalist of the prestigious Melvin L Marcus Young Investigator Award in Cardiovascular Science from the American Heart Association.
Yong-Yong Huang
VP of Business Development
Yong-Yong oversees strategy and development for ICA Therapeutics, LLC. For over five years, he has leveraged big data and analytics to solve complex business problems and developed strategies for large financial services companies. His experience entails increasing cashflow performance, optimizing operational performance and marketing strategies. Companies he has worked for includes Advance America and Shellpoint Mortgage Servicing, with clients including Meta Bank, Wells Fargo, MGIC, Capital Asset Management Group, and Sherman Financial Group.
Yong-Yong obtained a BBA in Marketing and International Business from Baylor University.
Kian-Keong Poh, MD
Principal Investigator – Singapore
Dr. Poh Kian Keong oversees the Phase II trial for Reperlin in Singapore. He is presently a Senior Consultant, Director of Postgraduate Education and Clinical Director of Research at the Department of Cardiology at The National University Heart Centre, Singapore.
His training in cardiology took place in Cardiac Department in NUH. Subsequently, he worked in St Elizabeth Medical Centre, Tufts University School of Medicine, Boston on novel therapies for cardiovascular conditions, including stem cell therapies. He then proceeded to the Massachusetts General Hospital, Harvard Medical School for training in echocardiography. He is certified by the National Board of Echocardiography (USA).
A/Prof Poh graduated with medical degrees from Cambridge University, UK, obtained his Master of Medicine in Internal Medicine from the National University of Singapore. He is a Fellow of the Royal College of Physicians, Edinburgh, the American College of Chest Physician, the American College of Cardiology and the American Society of Echocardiography.
In addition, A/Prof Poh is also a Council Member of the Singapore Cardiac Society and a Specialist / Cardiologist registered with the Academy of Medicine, Singapore.
He has multiple publications including many in high-impact factor journals and is a reviewer for several international medical journals. He is Editor of PULSE, a bi-annual publication of NUHCS and Associate Editor of the Singapore Medical Journal.
Charles Y. Lui, MD
Principal Investigator – USA
Dr. Lui is a Professor of Medicine at the University of Utah. Dr. Lui studied Chemistry at University of Nebraska and graduated with a Bachelor of Arts. He subsequently obtained a Master’s of Science in Biochemistry and a medical degree from University of Nebraska. Dr. Lui completed an Internal Medicine Residency at University of Nebraska, and subsequently completed his Clinical Cardiology fellowship. Dr. Lui completed an additional fellowship in Clinical Cardiology and NIH NHLBI Cardiovascular training at University of Texas Health Science Center.
Dr. Lui is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. He is the Director of Cardiac Catheterization and Chief of Cardiology at Salt Lake VA Medical Center.